Skip to main content

Table 6 Sensitivity of the adjusted CET for ultra-orphans to the R&D and other life-cycle costs assumption.

From: Establishing a reasonable price for an orphan drug

  All costs decrease in the same proportion than the R&D cost Only R&D costs decrease for ultra-orphan drugs
Orphan cut-off point £37,534 £39,260
Ultra-orphan cut-off point £938,358 £981,507
  1. Base case estimates are shown in italics
\